Skip to content
Home/Companies/Biotech/ImCheck Therapeutics
IT

ImCheck Therapeutics

Biotech·France·Exited 2025·Held 8yr

ImCheck Therapeutics is a TMT company, headquartered in France.

Entry
2017
Hold
8yr
Exit
2025
Est. EV
–

Who owns ImCheck Therapeutics?

ImCheck Therapeutics was owned by Boehringer Ingelheim Venture Fund through Boehringer Ingelheim Venture Fund (2010 vintage) from 2017 to 2025, exited via Trade Sale. Across its history, ImCheck Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Boehringer Ingelheim Venture Fund
Most recent investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen
2 ownership periods · full history below

Key facts

HQFrance
SectorTMT

Ownership history

2 ownership periods

Exited
Last exited in 2025 to .
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture FundExited 2025
2017 · 2025 · Boehringer Ingelheim Venture Fund · 2010 · Evergreen
Trade Sale · to
MOIC
–
Gimv
GimvExited 2025
exited 2025 · Gimv Portfolio
Trade Sale · to
MOIC
–

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

ProTgen
Active
BiotechUnited States· 2024
Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024
Aurobac Therapeutics
Active
BiotechFrance· 2023
Glox Therapeutics
Active
BiotechUnited Kingdom· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings